Skip to main content

Table 3 Overview of cost-effectiveness analyses

From: A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies

First author
Study year
ILD Model Perspective Time horizon Treatment (tx) Tx cost Tx QALY /person Control Control cost Control QALY /person ICER INB
Pharmacologic therapies
Clay [22]
2019
IPF Markov Societal Lifetime Nintedanib 140,486 4.50 Pirfenidone 133,592 5.20   9,849 -41,894
Porte [24]
2018
IPF Markov Societal Lifetime Nintedanib 109,100 3.34 Pirfenidone 118,025 3.29 -178,500 11,425
Rinciog [26]
2017
IPF Markov UK NHS & PSS Lifetime Nintedanib 148,950 3.50 Pirfenidone 152,986 3.45 -80,720 6,536
Loveman [25]
2015
IPF Markov UK NHS & PSS Lifetime Nintedanib 272,273 4.01 Pirfenidone 128,523 3.34 214,552 -110,250
Rinciog [28]
2020
IPF Markov Healthcare payer Lifetime Nintedanib 138,191 3.36 Pirfenidone 151,705 3.28 -168,925 17,514
Clay [22]
2019
IPF Markov Societal Lifetime Nintedanib 140,486 4.50 BSC 19,039 3.80 173,496 -86,447
Porte [24]
2018
IPF Markov Societal Lifetime Nintedanib 109,100 3.34 BSC 22,056 2.98 241,789 -69,044
Rinciog [26]
2017
IPF Markov UK NHS & PSS Lifetime Nintedanib 148,950 3.50 BSC 38,076 3.10 277,185 -90,874
Loveman [25]
2015
IPF Markov UK NHS & PSS Lifetime Nintedanib 272,273 4.01 BSC 6,014 2.98 258,504 -214,759
Clay [22]
2019
IPF Markov Societal Lifetime Pirfenidone 133,592 5.20 BSC 19,039 3.80 81,824 -44,553
Porte [24]
2018
IPF Markov Societal Lifetime Pirfenidone 118,025 3.29 BSC 22,056 2.98 309,577 -80,469
Rinciog [26]
2017
IPF Markov UK NHS & PSS Lifetime Pirfenidone 152,986 3.45 BSC 38,076 3.10 328,314 -97,410
Loveman [25]
2015
IPF Markov UK NHS & PSS Lifetime Pirfenidone 128,523 3.34 BSC 6,014 2.98 340,303 -104,509
Non-pharmacologic therapies
Whitty [27]
2019
IPF Decision tree UK NHS 2 weeks Ambulatory oxygen 128* 3.70* No oxygen - - 35 184,872
Groen [23]
2004
Any ILD MS Societal Lifetime Lung transplantation 138 M 1203 No lung transplant 71.25 M 738 143,548 -17 M
  1. The incremental cost effectiveness ratio (ICER) is the cost per additional quality adjusted life year (QALY) for a given treatment. The incremental net benefit (INB) was calculated using a willingness to pay value of $50,000. INB values > 0 represent cost-effective interventions (bold text). Costs are shown in 2020 USD. *Cost and KBILD values for each of the treatment and control groups were not available. The incremental cost and KBILD score are shown, with the ICER representing the cost per unit increase in KBILD. Abbreviations: KBILD, King’s Brief Interstitial Lung Disease; M, million; MS, microsimulation; PSS, personal social services; Tx, treatment; UK NHS, United Kingdom National Health Service